Ascentage Pharma Group Internat
AAPG · Nasdaq · USD · Market cap $1.2B · 767 employees
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price11.97 USD at the 20 Nov 2026 close
- Fair valueUnder review: our model's value is 2.94x the price, above our 2.00x limit.
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-20).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Ascentage Pharma Group Internat holds its Markup at $11.97. The statistical read favours the buyers, held for 4 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the buyers, held for 4 days |
| Price at the screen | $11.97 |
| Valuation | N/A trailing · -20.31 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.77 |
Five Screens: AAPG's Results
FAIL. Debt ratio
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 49.95% | Below 33% | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Pass |
| Receivables | 68.56% | Below 49% | Fail |
| Revenue purity | 14.30% | Below 5% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Ascentage Pharma Group Internat's business is in a permissible area, but its interest-bearing debt is about 50% of the company, well over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when AAPG's ethical verdict changes
Today AAPG does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model's value is 2.94x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
The Street's RangeStreet: 10 covering, consensus Strong Buy. Average target +280%.
China Biotech Chasing Cures Burns Cash Fast
Picture a clinical stage firm in China pushing one lead drug for tough cancers while revenue jumps 117 percent yet margins sit at minus 216 percent. Ascentage shows real pipeline movement and clears our ethical screen, yet the opportunity rating stays at none because forward earnings are deeply negative, return on equity is minus 155 percent and any moat remains unknown despite analyst targets near 48 dollars.
The double fair value gap looks tempting on the surface, but a pre profit biotech with that scale of losses rarely rewards patience once trials slip or funding needs grow. China regulatory and currency exposure add further layers that standard growth metrics do not capture.
We therefore step aside even though the science may one day deliver. Analysis, not advice.
| Forward P/E | -20.3x |
| EPS, trailing | -2.26 |
| EPS, forward | -0.65 |
| Revenue growth | +29.3%strong top-line growth |
| Profit margin | -228.5%currently unprofitable |
| Return on equity | -236.6%not currently earning a positive return on equity |
| FCF yield | -78.00% |
| Debt to equity | 3.70heavy leverage: higher risk if revenue softens |
| Current ratio | 1.22adequate liquidity, worth monitoring |
| Beta | 0.77steadier than the market |
| Short interest, float | 0.00% |
| 52-week range | 13.12 - 33.09 |
| Market cap | $1.2B |
| Employees | 767 |
AAPG-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to China and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from distribution to markup since the last review.
The framework has shifted from markdown to distribution since the last review.
The framework has shifted from distribution to markdown since the last review.
The framework has shifted from markdown to distribution since the last review.
Ethical screening: FAIL (changed).
Ethical screening: PASS.
Written on its date, before the outcome; never pruned.
- Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026 Yahoo Finance · 17d ago
- Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London Yahoo Finance · 18d ago
- Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL Yahoo Finance · 20 Oct 2026
- Ascentage Pharma (SEHK:6855) Stock Looks Above Fair Value After The Fall Yahoo Finance · 19 Oct 2026
- Ascentage Pharma to Participate in Four Upcoming Investor Conferences Yahoo Finance · 2 Sep 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $21.50 | -20.6% | · | $794 | -20.6% |
| 2 months | $25.33 | -32.6% | · | $674 | -32.6% |
| 3 months | $24.22 | -29.5% | · | $705 | -29.5% |
| 6 months | $29.48 | -42.1% | · | $579 | -42.1% |
| 1 year | $29.88 | -42.9% | · | $571 | -42.9% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever AAPG does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.